Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

PC89 Anti-Bcl-xs (Ab-1) (119-131) Rabbit pAb

Anti-Bcl-xs (Ab-1) (119-131) Rabbit pAb MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
PC89
  
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Tabulka spec. kláve

Host
Rb
Description
Overview

This product has been discontinued.





Recognizes the ~16 kDa Bcl-xs protein in doxorubicin-treated MCF-7 cells. Does not cross-react with Bcl-xL.
Catalogue NumberPC89
Brand Family Calbiochem®
Application Data
Detection of Bcl-xs by immunobloitting. Sample: Whole cell lysate from doxorubicin-treated MCF7 cells. Primary antibody: Anti-Bcl-xs (Ab-1) (119-131) Rabbit pAb (Cat. No. PC89) (2.5 µg/ml). Detection: chemiluminescence.
References
ReferencesBargou, R.C., et al. 1995. Eur. J. Immunol. 25, 770.
Dole, M.G., et al. 1995. Cancer Res. 55, 2576.
Zhang,H., et al. 1995. Biochem. Biophys. Res. Commun. 208, 950.
Fang, W., et al. 1994. J. Immunol. 153, 4388.
Krajewski, S., et al. 1994. Cancer Res. 54, 5501.
Nunex, G. et al. 1994. Immunol. Today 15, 582.
Boise L.H., et al. 1993. Cell 74, 597.
Cazais-Hatem, D.L., et al. 1992. Biochim. Biophys. Acta 1132, 109.
Product Information
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Positive controlDoxorubicin-induced MCF7 or HeLa cells or thymocytes
Preservative≤0.1% sodium azide
Applications
Key Applications Immunoblotting (Western Blotting)
Paraffin Sections
Application NotesImmunoblotting (2.5 µg/ml)
Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
Application CommentsThis antibody will not react with bcl-xL, but additional higher molecular weight bands may be seen with some cell lines. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena synthetic peptide (AYQSFEQDTFVEL) corresponding to amino acids 119-131 of human Bcl-xS
ImmunogenHuman
HostRabbit
IsotypeIgG
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
PC89 0

Documentation

Anti-Bcl-xs (Ab-1) (119-131) Rabbit pAb MSDS

Title

Safety Data Sheet (SDS) 

Anti-Bcl-xs (Ab-1) (119-131) Rabbit pAb Certificates of Analysis

TitleLot Number
PC89

References

Přehled odkazů
Bargou, R.C., et al. 1995. Eur. J. Immunol. 25, 770.
Dole, M.G., et al. 1995. Cancer Res. 55, 2576.
Zhang,H., et al. 1995. Biochem. Biophys. Res. Commun. 208, 950.
Fang, W., et al. 1994. J. Immunol. 153, 4388.
Krajewski, S., et al. 1994. Cancer Res. 54, 5501.
Nunex, G. et al. 1994. Immunol. Today 15, 582.
Boise L.H., et al. 1993. Cell 74, 597.
Cazais-Hatem, D.L., et al. 1992. Biochim. Biophys. Acta 1132, 109.

Brochure

Title
Caspases and other Apoptosis Related Tools Brochure
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision16-October-2007 RFH
ApplicationImmunoblotting (2.5 µg/ml)
Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
Application Data
Detection of Bcl-xs by immunobloitting. Sample: Whole cell lysate from doxorubicin-treated MCF7 cells. Primary antibody: Anti-Bcl-xs (Ab-1) (119-131) Rabbit pAb (Cat. No. PC89) (2.5 µg/ml). Detection: chemiluminescence.
DescriptionPurified rabbit polyclonal antibody. Recognizes the ~16 kDa Bcl-xs protein.
BackgroundBcl-x is a bcl-2-related gene that can function as a regulator of programmed cell death (apoptosis) independent of bcl-2. Alternative splicing results in two distinct bcl-x mRNAs2. The larger mRNA gives rise to a protein product, bcl-xL, which is similar in size and predicted structure to bcl-2. Like the long form, the short form (bcl-xs), contains a putative transmembrane domain which is responsible for its mitochondrial localization. The bcl-xs protein is generated following a deletion of 63 amino acids from the long form by the usage of a different 5' splice site in the first coding exon. The segment deleted corresponds to the region of highest homology among bcl-2 proteins derived from multiple species5. bcl-xs lacks the conserved BH1 and BH2 domains which are present in most members of the bcl-2 gene family. Studies have shown that bcl-xs can form heterodimers with bcl-2 and does so via codons 24-78. Tissue expression of bcl-xs is different from that seen for the long form of the protein, as is the regulation of the gene expression. bcl-xs appears to be critical in the development of the vertebrate immune system playing a central role in the establishment of the T cell compartment.
HostRabbit
Immunogen speciesHuman
Immunogena synthetic peptide (AYQSFEQDTFVEL) corresponding to amino acids 119-131 of human Bcl-xS
IsotypeIgG
Specieshuman, not mouse, not rat
Positive controlDoxorubicin-induced MCF7 or HeLa cells or thymocytes
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsThis antibody will not react with bcl-xL, but additional higher molecular weight bands may be seen with some cell lines. Antibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Yes
Toxicity Standard Handling
ReferencesBargou, R.C., et al. 1995. Eur. J. Immunol. 25, 770.
Dole, M.G., et al. 1995. Cancer Res. 55, 2576.
Zhang,H., et al. 1995. Biochem. Biophys. Res. Commun. 208, 950.
Fang, W., et al. 1994. J. Immunol. 153, 4388.
Krajewski, S., et al. 1994. Cancer Res. 54, 5501.
Nunex, G. et al. 1994. Immunol. Today 15, 582.
Boise L.H., et al. 1993. Cell 74, 597.
Cazais-Hatem, D.L., et al. 1992. Biochim. Biophys. Acta 1132, 109.